Telik was a life science start-up engaged in high-risk drug invention. In this webinar, Steve will tell the 21- year tale of the birth, rise and demise of Telik, which at one point, was valued at ~$1.5 billon USD. This is the story of how it all unfolded from the beginning then faded away into the vast landscape of bygone failed biotech companies.
Ultimately, Telik vanished into nothingness without a trace, except in the memories of the handful of employees who experienced the grand adventure of a lifetime.
Steve was the Vice President of Research and Development at Telik, Inc. until his retirement in 2014. He has more than 45 years of pharmaceutical, biotech and agrichemical industrial R&D experience. He holds a doctorate in chemistry from the University of California at San Diego and completed postdoctoral training at the University of California at Los Angeles and the University of Pennsylvania. He has been a SPARK advisor since 2008 where he provides drug development mentoring to SPARK-teams, including SPARK Global teams upon request. He also furnishes business development guidance to those projects selected for annual VC-Events, such as JP Morgan, BIO and BIO Investor Forum.
This webinar will be hosted by SPARK FLI.
Online via Zoom | Please register here!
Registration to the webinar is required in advance. Please register no later than 3th December 2024.Please note that you will receive the MS Teams Meeting link and access code the evening before the lecture and that access to last minute registrations, cannot be guaranteed.
SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Poland, SPARK Tel Aviv, SPARK Denmark, SPARK Zürich and SPARK at the Faculty of Medicine, Masaryk University. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.
